Ted W. Love, MD, president and CEO of Global Blood Therapeutics (GBT), defended the list price of his company’s recently-approved sickle-cell disease drug Oxbryta™ (voxelotor) before an audience of investors in New York . . .
Global Blood Therapeutics CEO Defends Price of Sickle-Cell Drug Oxbryta
Ted W. Love, MD, Details Company’s Sickle Cell Disease Approach, Defends Industry
Ted W. Love, MD, President and CEO of Global Blood Therapeutics (GBT), says the efficacy of Oxbryta™ and its pricing below the average for orphan drugs are among justifications for its $125,000-a-year cost, rejecting criticism over the drug’s price from the nonprofit Institute for Clinical and Economic Review (ICER). [Global Blood Therapeutics via YouTube]
![Knocking out BCL11A switches cellular production of hemoglobin from mutated adult form to normal fetal form.[Sebastian Kaulitzki - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Oct14_2011_812038_BloodCells_SickleCellBresearch1021341131-100x70.jpg "Single Gene Inactivation Triggers Fetal Hemoglobin Production and Corrects Sickle Cell Disease in Adult Mice")